Podcasts about blys

Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month's American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury's editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury's editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech's therapy. BioCentury's editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year's event. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/655751#biotech #biopharma #pharma #lifescience #AAN #AACR00:01 - Sponsor Message: RemeGen Co.01:02 - Myasthenia Gravis at AAN08:31 - RemeGen's Telitacicept18:03 - AACR: Targets and TrendsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Welcome back to Witching Hour: the show that looks at what's exciting, delighting, intriguing, and frustrating us as we make work, work alongside parenting. It's Ready or Not's loose little sister coming to your ears every Monday.In today's episode, we cover:Beers and Braids is the best thing we've ever heard of.What does sport have to do with career success for women?“As a mother”: the worst three words in the English language by Bibi Lynch for The Independent.I'm in My 40s, Child-Free and Happy. Why Won't Anyone Believe Me? By Glynnis MacNicol for the New York TimesAnd your answers to our questions about friendships between parent and non-parent friends (and why, as Nell Frizzell puts it, a woman in her thirties is painfully defined as either a mother or non-mother).Plus, so much more (beers and braids, anyone).---This episode of Witching Hour is brought to you by Blys - the app that makes prioritising self care easier than ever.With Blys you can book an in-home massage, beauty or wellness treatment with a qualified and trusted professional that comes to you.Blys brings you self-care, your way, on your schedule.Go to getblys.com.au and use the code “RON15” to save $15.---Thanks for listening to Witching Hour!If you liked the show, please tell your friends, subscribe or write a review.You can also find us on Instagram at readyornot.pod.This podcast was recorded on the lands of the Boon Wurong people of the Kulin Nation.The land on which I''m lucky enough to raise my son always was and always will be Aboriginal land.We Pay The Rent and you can too here.

From deciding on a whim to pack up her little Mitsubishi and leave Brisbane for the glossy magazines of Sydney, to the stone she received from a magic healing man in India that remained taped to her body throughout an entire pregnancy, Bronwyn McCahon has tales to tell, so it's no wonder she's spent the good part of her career in magazines and media.She's edited some of the biggest titles in the country, she's rubbed shoulders with the likes of Beyonce and Tommy Hilfiger, and in amongst it all, she's raised three children.Here, we talk working during the golden era of magazines, knowing when it was time to shift gears, and why as a parent, it's important not to give up everything for your kids.And just a note, we also discuss her experience with pregnancy loss.______This episode of Ready or Not is brought to you by Blys - the app that makes prioritising self care easier than ever.With Blys you can book an in-home massage, beauty or wellness treatment with a qualified and trusted professional that comes to you.Blys brings you self-care, your way, on your schedule. Go to getblys.com.au and use the code “RON15” to save $15.______Find Bronwyn's brand here: @play_etc.Thanks for listening to Ready or Not! If you liked the show, please tell your friends, subscribe or write a review. You can also find us on Instagram at readyornot.pod.This podcast was recorded on the lands of the Boon Wurong people of the Kulin Nation. The land on which I''m lucky enough to raise my son always was and always will be Aboriginal land.I Pay The Rent and you can too here.

Watch this episode on YouTube: https://youtu.be/lTYY6M8aeQ0 1st Segment (0:0:00 - 0:30:00) Hear what Michael has to say about: * App Developer Fiasco * The Beefs on Clubhouse app * McCormick buying Cholula Hot Sauce * Elon Musk now the 2nd richest man * Square buys Credit KarmaTax * 73° hot or cold, what's the difference? 2nd Segment (0:31:00 - 1:30:00) Join Michael and wife Bly talk about: * Blys off day off * Asking for “permission” in a marriage * Corona Virus * Dating cousins * Online Dating Enjoy! Find more of Bly: Instagram @Blythabee Your Host Michael Aigbedion: Instagram @saymichael Facebook @saymichaeljr Twitter @saymichael Snapchat @saymichaeljr Email us at: Michael@thewaterboysinc.com Send Mail to: P.O Box 166053 Irving Texas 75062

Prædiken af Filip Kildeholm til aftengudstjenesten på første søndag i advent d. 3. december 2017.

This podcast is about "On Demand Services" for This Mobile Life (S01E07). My guest was Ilter Dumduz, co-founder of Blys. Blys provides on-demand mobile massage service in Sydney (http://getblys.com.au). I'm very excited to have Ilter as a guest as he's worked in product management at Freelancer, Domain and GlamCorner. It was an awesome interview discussing on-demand services, marketplaces, and product craft. I hope you like it as much as I did chatting with Ilter. If you have any feedback, please leave us a review on iTunes or Soundcloud. If you want to reach out to me, hit me up on twitter @inspiredworlds. SHOW NOTES Prop 1 in Austin affects Uber & Lyft on demand services (http://austininno.streetwise.co/2016/05/06/austins-vote-on-uberlyft-is-today-heres-what-you-need-to-know) Airbnb host protection insurance policy (https://www.airbnb.com.au/host-protection-insurance) Lean Analytics by Alistair Croll & Benjamin Yoskovitz (http://leananalyticsbook.com) 666 Roadmap (http://inspiredworlds.com/restraint-makes-better-apps)

Matt Davis plays guitar, writes songs and sings with local rock band The Tim Blys. In this first ever, experimental version of Talking With Musicians [...]

http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

http://www.StockMarketFunding.com Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Wall St is hyping the suicidal results. We believe today's "pre market" manipulation in price action caused some large institutions to take a short position going into the move and the FDA Program Schedule Released at 8 AM today did not show any meaningful new data. Premarket high was $29.50 and now we're trading at $24.50 $5 dollars lower. The new breakthrough in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.

New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. SMF will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies – antibodies that attack and destroy the body’s own healthy tissues.BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the United States and Europe. The FDA has granted BENLYSTA a priority review designation with a Prescription Drug User Fee Act (PDUFA) target date of December 9, 2010 – so it is possible that BENLYSTA could receive regulatory approval in the United States before the end of 2010.